Contineum Therapeutics, Inc. (CTNM) Earnings History
Net Loss5 years of earnings data (2021–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Contineum Therapeutics, Inc. (CTNM) Earnings Overview
As of October 3, 2026, Contineum Therapeutics, Inc. (CTNM) reported trailing twelve-month net income of -$58M, reflecting -33.1% year-over-year growth. The company earned $-1.54 per diluted share over the past four quarters.
Looking at the long-term picture, CTNM's historical earnings data spans multiple years. The company achieved its highest annual net income of $23M in fiscal 2023.
Contineum Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$538M net income), PRTA (-$44M net income, -2520.6% margin), ARQT ($29M net income, -4.3% margin), CTNM has comparable earnings metrics. Compare CTNM vs IMVT →
CTNM Earnings vs Peers
Earnings metrics vs comparable public companies
CTNM Historical Earnings Data (2021–2025)
5 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$60M | -41.9% | -$68M | $-2.17 | - | - |
| 2024 | -$42M | -286.0% | -$51M | $-1.63 | - | - |
| 2023 | $23M | +193.7% | -$16M | $0.13 | 45.4% | -32.2% |
| 2022 | -$24M | +16.4% | -$23M | $-0.97 | - | - |
| 2021 | -$29M | - | -$29M | $-1.15 | - | - |
Download Data
Export CTNM earnings history in CSV or JSON format
Free sign-in required to download data
CTNM Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CTNM — Frequently Asked Questions
Quick answers to the most common questions about buying CTNM stock.
What is CTNM earnings per share (EPS)?
CTNM trailing twelve-month (TTM) diluted EPS is $-1.54, reflecting -33.1% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2021 to 2025 is available in the table on this page.
What is Contineum Therapeutics, Inc.'s net income?
Contineum Therapeutics, Inc. (CTNM) trailing twelve-month net income is $-58M as of 2025. Earnings declined -33.1% year-over-year.
Is CTNM profitable?
CTNM is not currently profitable on a TTM basis, reporting a net loss of $-58M. Net margin is N/A. Investors should monitor for a return to profitability.
What is CTNM's earnings growth rate?
CTNM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2021 to 2025.
What are CTNM's profit margins?
Contineum Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -26.1%.
Is CTNM growing earnings?
CTNM earnings are declining — EPS fell -33.1% year-over-year. TTM net income dropped to $-58M. This contrasts with the 5-year CAGR of N/A.
What was CTNM's best earnings year?
Contineum Therapeutics, Inc.'s highest annual net income on record is $23M, achieved in fiscal year 2023. Earnings history on this page spans 2021 to 2025 and includes all annual and quarterly figures.
What were CTNM's earnings last quarter?
CTNM's most recent reported quarter was Q2 2026. Net income was $-15M with diluted EPS of $-0.40. For a full breakdown of all quarters, see the quarterly earnings table on this page.